Background
Bacteremic infections caused by Staphylococcus aureus have been reported with increasing frequency, and it has emerged as a leading cause of infective endocarditis (IE) in many regions of the world [1‐3]. Endocarditis has been observed in 11% to 35% of S. aureus bacteremias (SAB) attributable to different sets of diagnostic criteria [4‐6]. S. aureus endocarditis is associated with higher occurrence of extracardiac deep infections due to metastatic spread, thromboembolic complications, and a high mortality compared with IE caused by other pathogens [1, 2].
The incidence of endocarditis has not been changed during the past two decades [7, 8] but classic risk factors such as rheumatic heart disease are being replaced by new groups, including injection drug users (IDUs), elderly patients with degenerative valve disease, patients with intravascular catheter or prosthetic valve, and nosocomial acquisition [2, 3, 8]. One of the reasons for increased incidence of S. aureus in IE is injection drug abuse [9‐11]. Colonization with S. aureus, HIV-related immunosuppression, female sex, increasing injection drug use frequency, and a history of previous IE are associated with a higher risk for endocarditis [11, 12].
Anzeige
Right-sided involvement, younger age, and lack of pre-existing heart disease or other underlying diseases have been thought to explain the better prognosis of S. aureus endocarditis among IDUs than in general population [2, 13‐15]. Therefore, surgery is less frequently needed and shorter antibiotic courses have been used in IDUs [16, 17]. Drug abusers tend to have fewer arterial embolic events or strokes than nonaddicts [13, 18]. These differences between IDUs and general population have been derived from non-comparative trials, and there are only few studies where the clinical picture of S. aureus endocarditis in these patient groups has been compared [2, 13, 14, 19].
We collected prospectively a large patient population with SAB and compared the risk factors, clinical, and echocardiographic findings as well as outcome of endocarditis in IDUs and in general population.
Methods
Patient population
Prospectively randomized adult patients with blood culture positive for S. aureus from 5 university hospitals and 7 tertiary care hospitals in Finland were taken into the trial from January 1999 to May 1999 and from January 2000 to August 2002. Originally, the trial was designed for evaluation on the effect of fluoroquinolone (trovafloxacin or levofloxacin) given in addition to most effective standard treatment in SAB [20] [see Additional file 1]. Clinical, pathological, and echocardiographic data of patients with definite or possible IE according to modified Duke criteria were collected [21], and these cases were included into the analysis. The protocol was approved by the ethics committees of all study sites, and written informed consent was obtained from all patients or their representatives. The trial was conducted in accordance with the Declaration of Helsinki.
The exclusion criteria were age younger than 18 years, imprisonment, proven or suspected pregnancy, breastfeeding, epilepsy, another bacteremia during the previous 28 days, polymicrobial bacteremia (≥ 3 microbes), history of allergy to any quinolone antibiotic, previous tendinitis during fluoroquinolone therapy, prior fluoroquinolone use for more than 5 days before randomization, positive culture for S. aureus only from a central intravenous catheter, meningitis, neutropenia (< 0.5 × 109/L), or failure to supply an informed consent. Patients with bacteremia due to methicillin-resistant S. aureus (MRSA) and a S. aureus strain resistant to any fluoroquinolone were also excluded.
Anzeige
Definitions
IDUs were defined as patients who had injected drugs within the past 6 months before randomization. Routine bacteriological methods were used to detect S. aureus growth in blood [20] [see Additional file 1]. Bacteremia was hospital-acquired if the first positive blood culture was obtained ≥ 48 hours after admission, or the patient was a resident in a long-term care facility or attended hemodialysis within the preceding 2 months. Prognosis or severity of underlying diseases were classified as healthy, nonfatal, ultimately, or rapidly fatal according to the criteria of McCabe and Jackson [22]. Severe sepsis at the time of first blood culture positive for S. aureus was defined as an infectious process leading to organ dysfunction or signs of hypoperfusion or hypotension [23].
The infection focus was documented by clinical, bacteriological, radiological, or pathological investigations. Intravenous catheter-associated bacteremia was defined using the guidelines of the Infectious Diseases Society of America [24]. Extracardiac deep infection was defined as pneumonia, deep-seated abscess, osteomyelitis, septic arthritis, meningitis, septic thrombophlebitis, mediastinitis, urinary tract infection, infection of any extracardiac prosthetic device, or recurrent SAB. Clinical findings of IE such as documentation of a new valvular regurgitant murmur, or evidence of any vascular phenomena such as infarction and embolic event or intracranial hemorrhage were detected. Endocarditis of prosthetic valve was classified as early when occurring ≤ 60 days after valve replacement and as late > 60 days after valve replacement. Leucocytosis was determined if white blood cell count was over 12 × 109/L and leucopenia less than 4 × 109/L.
Echocardiography
Two-dimensional imaging from multiple tomographic planes and spectral Doppler and color flow imaging were used in all study sites. Transthoracic echocardiography (TTE) and/or transesophageal echocardiography (TEE) as clinically indicated were performed at the discretion of the treating physician and by experienced echocardiographers. The presence of cardiac vegetations, oscillation, paravalvular or intracardiac abscess, new valvular regurgitation, prosthetic valve dehiscence, and valve perforation were recorded [21].
Antibiotic treatment
The detailed information of the antimicrobial agents, doses, indications and duration of treatment have been described in our former article [20] [see Additional file 1]. All patients with endocarditis were assigned to receive initially cloxacillin or dicloxacillin (2 g q4 h) for 4 to 6 weeks intravenously. Alternatively, cefuroxime (1.5 g q6 h) or vancomycin (1 g bid) were allowed if a contraindication against the use of semisynthetic penicillins was noted. Aminoglycoside (either tobramycin or netilmicin at 1 mg/kg of body weight q8h) was added to the drug therapy described above for the first 7 days. Rifampicin (450 mg once daily for patients under 50 kg and 600 mg once daily for patients over 50 kg in weight, orally or intravenously) was recommended for at least 4 weeks when an endocarditis or an extracardiac deep infection was suspected or confirmed. Half of the patients were randomized to receive a fluoroquinolone either trovafloxacin or levofloxacin in addition to therapy above. Fluoroquinolone treatment was not observed to have an impact on mortality in SAB or in patients with IE [20] [see Additional file 1]. In cases of renal dysfunction the antibiotic doses were adjusted as recommended by the manufacturers.
Clinical outcome
All patients were prospectively followed for 3 months after the first positive blood culture for S. aureus. Case fatality rates were recorded at 7 days and 28 days, and at 3 months. Other outcome measures were site of valvular involvement, evidence of extracardiac deep infections or thromboembolic events, duration of fever (recorded in days until axillary temperature was < 37.5 C°), duration of hospitalization and need for cardiac surgery. Laboratory tests were conducted on the day of the first positive blood culture for S. aureus.
Statistical analysis
Statistical analyses were performed with SPSS® version 12.0. (SPSS Inc., Chicago, IL, USA). Univariate analyses for categorical variables were calculated with chi-square test or Fisher's exact test as appropriate, and for continuous variables the Mann-Whitney test was used. Odds ratios (OR) with 95% confidence intervals (CI) were as association measures. Cox regression analysis was used to compare survival of IDUs with nonaddicts, and results were given as hazard ratios (HR) with 95% CI. Survival was calculated from the day of the first blood culture positive for S. aureus until 3 months. All tests were 2-tailed and P values of < 0.05 were considered significant.
Results
Patient characteristics
During the study period, 430 patients with S. aureus bacteremia were included into this trial. The included patients represented 31% of all SAB patients in study hospitals. Endocarditis was observed in 74 of 430 patients (17%), of whom 20 were IDUs and 54 were nonaddicts. Thus, IE was observed in 46% of all 44 IDUs and in 14% of all 386 nonaddicts with SAB (OR, 5.12; 95% CI, 2.65–9.91; P < 0.001). Patients with endocarditis differed from those with SAB only by having significantly more often a predisposing heart disease or a pre-existing liver disease (chronic hepatitis C infection in 19 patients and hepatic cirrhosis in 5 patients), but less preceding trauma (Table 1). Other predisposing characteristics and underlying diseases of the patients with IE did not differ from those with SAB.
Table 1
Characteristics of 430 patients with Staphylococcus aureus bacteremia with and without endocarditis.
Bacteremia with endocarditis | Bacteremia without endocarditis | Total | ||||
|---|---|---|---|---|---|---|
Characteristic | (n = 74) | (n = 356) | (n = 430) | OR | 95% CI |
P
|
Age, mean years ± SD | 55 ± 22 | 59 ± 17 | 58 ± 18 | - | - | 0.26 |
Male sex | 47 (64) | 221 (62) | 268 (62) | 1.06 | 0.63–1.79 | 0.82 |
Hospital-acquired | 34 (46) | 198 (56) | 232 (54) | 0.68 | 0.41–1.12 | 0.13 |
Previous skin disease or wound | 34 (46) | 189 (53) | 223 (52) | 0.75 | 0.45–1.24 | 0.26 |
Previous surgerya
| 18 (24) | 77 (22) | 95 (22) | 1.17 | 0.65–2.10 | 0.61 |
Trauma in prior 2 months | 12 (16) | 98 (28) | 110 (26) | 0.51 | 0.26–0.99 | 0.04 |
Central intravenous catheter | 10 (14) | 48 (14) | 58 (14) | 1.00 | 0.48–2.09 | 0.99 |
Hemodialysis | 6 (8) | 38 (11) | 44 (10) | 0.74 | 0.30–1.82 | 0.51 |
Previous S. aureus deep infection | 3 (4) | 28 (8) | 31 (7) | 0.50 | 0.15–1.67 | 0.33 |
Previous S. aureus bacteremia | 2 (3) | 15 (4) | 17 (4) | 0.63 | 0.14–2.82 | 0.75 |
Predisposing heart condition | 47 (64) | 63 (18) | 110 (26) | 8.10 | 4.69–13.98 | <0.001 |
Degenerative heart disease | 22 (30) | 32 (9) | 54 (13) | 4.28 | 2.31–7.94 | <0.001 |
Injection drug use | 20 (27) | 24 (7) | 44 (10) | 5.12 | 2.65–9.91 | <0.001 |
Prosthetic valve | 17 (23) | 1 (0.3) | 18 (4) | 105.88 | 13.82–811.08 | <0.001 |
Prior endocarditis | 11 (15) | 0 (0) | 11 (3) | - | - | <0.001 |
Congenital heart disease | 5 (7) | 5 (1) | 10 (2) | 5.09 | 1.43–18.05 | 0.02 |
Mitral valve prolapse | 2 (3) | 2 (1) | 4 (1) | 4.92 | 0.68–35.48 | 0.14 |
Rheumatic heart disease | 2 (3) | 1 (0.3) | 3 (1) | 9.86 | 0.88–110.21 | 0.08 |
Coronary artery disease | 21 (28) | 89 (25) | 110 (26) | 1.19 | 0.68–2.08 | 0.54 |
Corticosteroid use ≥ 1 month | 8 (11) | 37 (10) | 45 (11) | 1.05 | 0.47–2.35 | 0.92 |
Immunosuppressive therapyb
| 3 (4) | 26 (7) | 29 (7) | 0.54 | 0.16–1.82 | 0.45 |
Diabetes | 19 (26) | 89 (25) | 108 (25) | 1.04 | 0.58–1.84 | 0.90 |
Alcoholism | 4 (5) | 44 (12) | 48 (11) | 0.41 | 0.14–1.17 | 0.10 |
Liver disease | 24 (32) | 43 (12) | 67 (16) | 3.49 | 1.95–6.25 | <0.001 |
Malignancy | 9 (12) | 54 (15) | 63 (15) | 0.77 | 0.36–1.65 | 0.51 |
Chronic renal failure | 8 (11) | 52 (15) | 60 (14) | 0.71 | 0.32–1.56 | 0.39 |
HIV positive | 3 (4) | 5 (1) | 8 (2) | 2.97 | 0.69–12.70 | 0.14 |
Among patients with endocarditis, IDUs as a group were younger and had less predisposing heart conditions, coronary artery disease or diabetes than nonaddicts (Table 2). When the underlying diseases were grouped by the predicted prognoses (McCabe's classification), none among the IDUs had a rapidly fatal or ultimately fatal disease but they were found in 20 of 54 nonaddicts (37%) (P = 0.001). However, there were three IDUs with HIV infection.
Table 2
Characteristics of injection drug users and nonaddicts with Staphylococcus aureus endocarditis.
Injection drug users | Nonaddicts | ||
|---|---|---|---|
Characteristic | (n = 20) | (n = 54) |
P
|
Age, mean years ± SD | 27 ± 15 | 65 ± 15 | <0.001 |
Male sex | 15 (75) | 32 (59) | 0.28 |
Hospital-acquired | 1 (5) | 33 (61) | <0.001 |
Previous skin disease or wound | 12 (60) | 22 (41) | 0.19 |
Previous surgerya
| 0 (0) | 18 (33) | 0.002 |
Trauma in prior 2 months | 3 (15) | 9 (17) | 1.00 |
Central intravenous catheter | 0 (0) | 10 (19) | 0.05 |
Hemodialysis | 0 (0) | 6 (11) | 0.18 |
Previous S. aureus deep infection | 2 (10) | 1 (2) | 0.18 |
Previous S. aureus bacteremia | 2 (10) | 0 (0) | 0.07 |
Predisposing heart condition | 4 (20) | 27 (50) | 0.03 |
Degenerative heart disease | 0 (0) | 22 (41) | <0.001 |
Prosthetic valve | 0 (0) | 17 (32) | 0.004 |
Prior endocarditis | 1 (5) | 10 (19) | 0.27 |
Congenital heart disease | 3 (15) | 2 (4) | 0.12 |
Mitral valve prolapse | 0 (0) | 2 (4) | 1.00 |
Rheumatic heart disease | 0 (0) | 2 (4) | 1.00 |
Coronary artery disease | 0 (0) | 21 (39) | <0.001 |
Corticosteroid use ≥ 1 month | 0 (0) | 8 (15) | 0.10 |
Immunosuppressive therapyb
| 0 (0) | 3 (6) | 0.56 |
Diabetes | 1 (5) | 18 (33) | 0.02 |
Alcoholism | 0 (0) | 4 (7) | 0.57 |
Liver disease | 18 (90) | 6 (11) | <0.001 |
Chronic hepatitis C | 17 (85) | 2 (4) | <0.001 |
Hepatic cirrhosis | 1 (5) | 4 (7) | 1.00 |
Malignancy | 0 (0) | 9 (17) | 0.10 |
Chronic renal failure | 0 (0) | 8 (15) | 0.10 |
HIV positive | 3 (15) | 0 (0) | 0.02 |
Anzeige
Only one drug abuser had a hospital-acquired bacteremia and none associated with the use of the central intravenous catheter (Table 2). Severe sepsis was observed in 9 of 20 IDUs (45%) and in 28 of 54 nonaddicts (52%) without significant difference between the groups (P = 0.79).
Site of endocarditis
According to the modified Duke criteria for endocarditis, 56 patients (76%) were confirmed as definite (10 by pathologic criteria and 46 by clinical criteria), and 18 patients (24%) as possible (Table 3). Left-sided involvement was observed in 93% of nonaddicts whereas in 60% of IDUs had right-sided endocarditis (tricuspid valve involvement in all patients). Among nonaddicts aortic valve was slightly more often involved (44%) than mitral valve (35%).
Table 3
Classification, valvular involvement and echocardiographic findings of injection drug users and nonaddicts with Staphylococcus aureus endocarditis.
Injection drug users | Nonaddicts | Total | ||||
|---|---|---|---|---|---|---|
Variable | (n = 20) | (n = 54) | (n = 74) | OR | 95% CI |
P
|
Criteria, classificationa
| ||||||
Possible | 1 (5) | 17 (32) | 18 (24) | 0.12 | 0.01–0.93 | 0.03 |
Definite | 19 (95) | 37 (69) | 56 (76) | 8.73 | 1.08–70.67 | 0.03 |
Valvular involvementb
| ||||||
Left-sided | 6 (30) | 50 (93) | 56 (76) | 0.03 | 0.01–0.14 | <0.001 |
Aortic | 2 (10) | 24 (44) | 26 (35) | 0.14 | 0.03–0.66 | 0.006 |
Mitral | 3 (15) | 19 (35) | 22 (30) | 0.33 | 0.08–1.25 | 0.15 |
Aortic and mitral | 1 (5) | 7 (13) | 8 (11) | 0.35 | 0.04–3.07 | 0.44 |
Right-sided | 12 (60) | 4 (7) | 16 (22) | 18.75 | 4.83–72.73 | <0.001 |
Both sides | 2 (10) | 0 (0) | 2 (3) | - | - | 0.07 |
Echocardiography performed | 20 (100) | 53 (98) | 73 (99) | - | - | 1.00 |
TTE | 20 (100) | 52 (96) | 72 (97) | - | - | 1.00 |
TEE | 9 (45) | 40 (74) | 49 (66) | 0.29 | 0.10–0.84 | 0.03 |
Echocardiographyc
| ||||||
Vegetation | 14 (70) | 25 (47) | 39 (53) | 0.26 | 0.87–7.84 | 0.16 |
Regurgitationd
| 17 (85) | 35 (66) | 52 (71) | 2.91 | 0.75–11.27 | 0.15 |
Valve perforation | 1 (5) | 0 (0) | 1 (1) | - | - | 0.27 |
Paravalvular or intracardiac abscess | 1 (5) | 2 (4) | 3 (4) | 1.34 | 0.12–15.67 | 1.00 |
Duration of bacteremia before diagnosis, median days (range) | 2 (0–8) | 3 (0–28) | 3 (0–28) | - | - | 0.67 |
Prosthetic valve endocarditis, involving left side only, occurred in 17 of 74 patients (23%) and they all presented in nonaddicts. The most of these patients had an early onset of prosthetic valve IE (12 patients).
Echocardiographic findings
Echocardiography was performed in 263 of 430 patients (61%) with SAB. Addicts underwent echocardiography significantly more often (91%) compared with nonaddicts (58%) (OR, 7.31; 95% CI, 2.56–20.84; P < 0.001). In endocarditis, TTE was performed in 72 of 74 patients (97%) with no significant difference between IDUs and nonaddicts (Table 3). TEE was performed significantly more often in nonaddicts than in IDUs (74% vs 45%).
Anzeige
A vegetation was evident by echocardiography in 53% of cases and a new regurgitation in 71% of cases without significant differences between the groups (Table 3). Only 4 patients had an intracardial abscess or valve perforation.
Clinical manifestations and outcome
There were no differences in the clinical manifestations between the groups except the tendency for more frequent occurrence of various vascular phenomena among IDUs (Table 4). The most common infection focus was skin or soft tissue infection in 46 of 74 patients (62%). An extracardiac deep infection was found in 85% of IDUs and in 89% of nonaddicts (P = 0.70).
Table 4
Clinical manifestations of injection drug users and nonaddicts with Staphylococcus aureus endocarditis during 3 months follow-up.
Injection drug users | Nonaddicts | Total | ||||
|---|---|---|---|---|---|---|
Variable | (n = 20) | (n = 54) | (n = 74) | OR | 95% CI |
P
|
Skin or soft tissue | 12 (60) | 34 (63) | 46 (62) | 0.88 | 0.31–2.53 | 1.00 |
Central intravenous catheter | 0 (0) | 3 (6) | 3 (4) | - | - | 0.56 |
Extracardiac deep infectiona
| 17 (85) | 48 (89) | 65 (88) | 0.71 | 0.16–3.15 | 0.70 |
Pneumonia | 14 (70) | 27 (50) | 41 (55) | 2.33 | 0.78–6.98 | 0.19 |
Deep-seated abscessb
| 7 (35) | 25 (46) | 32 (43) | 0.63 | 0.22–1.81 | 0.44 |
Osteomyelitis | 6 (30) | 17 (32) | 23 (31) | 0.93 | 0.31–2.85 | 1.00 |
Septic arthritis | 3 (15) | 5 (9) | 8 (11) | 1.73 | 0.37–8.02 | 0.67 |
Urinary tract | 1 (5) | 4 (7) | 5 (7) | 0.66 | 0.07–6.27 | 1.00 |
Recurrent S. aureus bacteremia | 1 (5) | 1 (2) | 2 (3) | 2.79 | 0.17–46.84 | 0.47 |
Mediastinitis | 0 (0) | 9 (17) | 9 (12) | - | - | 0.10 |
Vascular phenomenon | 12 (60) | 19 (35) | 31 (42) | 2.76 | 0.96–7.93 | 0.07 |
Arterial thromboembolic event | 5 (25) | 17 (32) | 22 (30) | 0.73 | 0.23–2.32 | 0.78 |
Heartc
| 0 (0) | 11 (20) | 11 (15) | - | - | 0.03 |
Spleen, kidney or liver | 3 (15) | 0 (0) | 3 (4) | - | - | 0.02 |
Cerebral | 4 (20) | 9 (17) | 13 (18) | 1.25 | 0.34–4.63 | 0.74 |
Venous thromboembolic event | 8 (40) | 4 (7) | 12 (16) | 8.33 | 2.15–32.32 | 0.002 |
Pulmonary embolismd
| 8 (40) | 2 (4) | 10 (14) | 17.33 | 3.26–92.24 | <0.001 |
Deep venous thrombosis | 0 (0) | 2 (4) | 2 (3) | - | - | 1.00 |
Vascular complications, including arterial or venous thromboembolic events, were detected in 60% of IDUs but in only 35% of nonaddicts (P = 0.07) (Table 4). Especially, septic pulmonary embolism was observed only in IDUs. Whereas all coronary artery related diseases were among nonaddicts, all 3 parenchymal embolic events were observed in drug abusers. Congestive heart failure in acute phase was present in 11 of 74 patients (15%) with no difference between the groups. Two patients developed recurrent bacteremia during the 3 months follow-up period. There were no differences in median duration of fever (3 days) or median duration of hospitalization (32 days) between IDUs and nonaddicts (Table 5). Cardiac surgery was performed in 15% of IDUs but only in 7% of nonaddicts (OR, 2.21; 95% CI, 0.45–10.87; P = 0.38).
Table 5
Outcome and surgical treatment of injection drug users and nonaddicts with Staphylococcus aureus endocarditis.
Injection drug users | Nonaddicts | Total | ||
|---|---|---|---|---|
Outcome | (n = 20) | (n = 54) | (n = 74) |
P
|
Case fatality rate | ||||
At 7 days | 1 (5) | 6 (11) | 7 (9) | 0.67 |
At 28 days | 1 (5) | 16 (30) | 17 (23) | 0.03 |
At 3 months | 2 (10) | 21 (39) | 23 (31) | 0.02 |
Duration of fever, median days (IQR)a
| 3 (2–10) | 3 (0–6) | 3 (1–6) | 0.24 |
Duration of hospitalization, median days (IQR) | 32 (30–48) | 32 (20–47) | 32 (24–47) | 0.55 |
Cardiac surgery | 3 (15) | 4 (7) | 7 (9) | 0.38 |
Valve replacement | 1 (5) | 4 (7) | 5 (7) | 1.00 |
Valve repairb
| 3 (15) | 0 (0) | 3 (4) | 0.02 |
Case fatality rate of all patients with IE was 23% at 28 days, and 31% at 3 months (Table 5). Mortality was significantly higher in nonaddicts than in addicts at 28 days (OR, 8.00; 95% CI, 0.99–64.94; P = 0.03), and also at 3 months (OR, 5.73; 95% CI, 1.20–27.25; P = 0.02). Significant factors for lower mortality based on univariate analyses were injection drug abuse (HR, 0.22; 95% CI, 0.05–0.92; P = 0.04), age (HR, 1.03; 95% CI, 1.01–1.06; P = 0.006), and none or nonfatal underlying diseases by McCabe's classification (HR, 0.24; 95% CI, 0.10–0.54; P = 0.001). Statistically significant association for mortality were not found with the following: right-sided involvement (HR, 0.30; 95% CI, 0.07–1.30; P = 0.11), left-sided involvement (HR, 2.31; 95% CI, 0.69–7.78; P = 0.18), severe sepsis at the time of first positive blood culture for S. aureus (HR, 1.71; 95% CI, 0.74–3.95; P = 0.21), or arterial embolic events (HR, 2.15; 95% CI, 0.94–4.90; P = 0.07). After adjusting by age and underlying diseases, injection drug abuse was not significantly associated with lower mortality (HR, 0.74; 95% CI, 0.10–5.40; P = 0.77).
Anzeige
Laboratory data
At the time of first positive blood culture for S. aureus, leucocytosis was significantly more common in nonaddicts than in IDUs (55% vs 15%, respectively; P = 0.003), and only 2 patients (4%) had leucopenia. The median of serum C-reactive protein on the day of the first positive blood culture for S. aureus was 198 mg/L (range, 60–413 mg/L) in addicts compared with 171 mg/L (range, 5–478 mg/L) in nonaddicts without significant difference between the groups. Only 2 nonaddicts and none of IDUs had alanine aminotransferase level 2-fold above normal limit.
Antibiotic treatment
Sixty-five of 74 patients (88%) were treated with cloxacillin or dicloxacillin with no significant difference between the groups. Seven patients (10%) received cefuroxime, and one received vancomycin and one ceftriaxone. The median duration of parenteral antibiotic therapy from the first positive blood culture for S. aureus was 30 days (interquartile range, 24–43 days) in IDUs and 26 days (interquartile range, 13–34 days) in nonaddicts (P = 0.12), respectively.
An aminoglycoside was significantly more often given to addicts (19 of 20 patients) than to nonaddicts (29 of 54 patients) (OR, 16.38; 95% CI, 2.05–131.21; P = 0.001). Eighteen of 20 IDUs (90%) received rifampicin compared with 48 of 54 nonaddicts (89%) with no significant difference between the groups.
Discussion
To the best of our knowledge, this trial is one of the largest prospective evaluations on S. aureus endocarditis comparing patients with and without injection drug use [2, 13]. It is to be noted that our trial included only methicillin-sensitive S. aureus (MSSA) strains. MRSA strains are very rare in Finland (< 2% from all isolated S. aureus strains) and not a single endocarditis due to MRSA had to be excluded. Lack of MRSA might complicate extrapolation of these results into countries with high MRSA prevalence. However, MRSA endocarditis is usually more difficult to treat. While concentrating only on cases caused by MSSA strains real differences between IDUs and nonaddicts might be better revealed. In our trial, right-sided involvement predominated slightly in IDUs whereas almost all nonaddicts had left-sided endocarditis. In contrast to previous data the frequency of complications among IDUs was equal to that among nonaddicts. An extracardiac deep infection was observed also in most of the addicts. According to recent studies, deep infections seem to be more common in SAB than previously thought [20, 25] [see Additional file 1]. In the current trial, the frequency of arterial embolic events was similar in both groups, although they have been observed less frequently among IDUs in earlier studies [13, 18, 26]. However, mortality in addicts was significantly lower than in nonaddicts as reported previously [13, 14, 26, 27].
S. aureus is an important and a more common cause of IE, especially among IDUs [8, 11]. In a recent prospective multicenter study of 505 patients with SAB, endocarditis was found in 13% of all patients and in 35% of IDUs [6]. In agreement with that study, the incidence of IE was 17% among all SAB patients and 46% among IDUs in our trial. The proportion of definite IE in the present trial (76%) was also in line that observed in the other large survey [6].
Frequent use of echocardiography may increase the incidence of IE at least to some extent. Persistent bacteremia for over 3 days has been suggested to be a predictor for endocarditis [28] which was not designed for evaluation in our trial. We performed echocardiography as clinically indicated. It was done to 61% of SAB patients, and the rate was similar or higher compared with other studies [19, 25, 29]. Some endocarditis cases with atypical presentation might have been missed because echocardiography in our cohort as well as in previous studies was not performed for all SAB patients. The tricuspid valve was predominantly affected in addicts (60%), although the incidence was slightly lower than that reported previously (from 70% to 90%) [2, 13, 19, 30]. We presented that the frequency of left-sided involvement in addicts was as high as 30% which is similar to that in some studies [2, 10, 31], but higher than in most earlier reports with left-sided endocarditis ranging from 8% to 19% [16, 26, 30]. In IDUs, both sides of the heart are usually involved simultaneously in 5% to 10% of cases as detected in the current trial.
Extracardiac deep infections have been associated with SAB in left-sided endocarditis with the incidence ranging from 40% to 76% [20, 32‐34] [see Additional file 1]. In contrast to previous studies [13, 26, 35], deep infections in our trial occurred in over 80% in both IDUs and nonaddicts. Systemic thromboembolic events are well recognized complications in endocarditis occurring in 21% to 50% of cases, especially in patients with left-sided involvement and prosthetic heart valves, and are accompanied by high mortality rates [36‐39]. In earlier reports, IDUs had fewer arterial emboli or strokes than nonaddicts probably due to involvement of right-sided endocarditis [2, 18, 40]. In contrast, in our trial arterial thromboembolic events were observed with equal frequency in addicts and in nonaddicts. Venous embolic events were more common among addicts, and septic pulmonary embolism manifestated only in IDUs. However, the frequency of septic pulmonary embolism (40%) was less than the previously reported incidence of 67% to 87% in IDUs [40‐42].
Due to lack of controlled studies, indications for surgical approaches are not determined in patients with drug addiction [27]. Furthermore, doubts on compliance and continued drug abuse may reduce enthusiasm for surgery. Cardiac surgery is thought to be needed in only a small minority of cases in IDUs, and indications for surgical correction of right-sided involvement are not equally defined as for left-sided endocarditis [16, 41, 43]. However, some studies suggest that surgical treatment may clearly improve survival in IE among IDUs [10, 44]. In this trial, cardiac surgery was as common in IDUs as in nonaddicts (15% vs 7%), but valve repair was performed more often in addicts. The frequency of cardiac surgery in IDUs was high in light of prosthetic valve domination in nonaddicts in agreement with another recent study [2].
The duration of parenteral antibiotic treatment in SAB depends largely on the presence of an associated IE, in which 4 to 6 weeks therapy is recommended [15, 45, 46]. A shorter 2 weeks treatment has been suggested for selected cases of right-sided involvement with a good prognosis [17, 45]. Recommendations on duration of aminoglycoside are variable. For left-sided native valve endocarditis 3–5 days therapy is suggested but as long as 2 weeks for right-sided involvement has been used [47, 48]. In addition, two small studies have demonstrated oral fluoroquinolone and rifampicin for 4 weeks to be as effective as the standard intravenous therapy in right-sided endocarditis [49, 50]. In our cohort, the high proportion of extracardiac deep infections in addicts extended the intravenous antibiotic therapy to 4 weeks. This observation suggest that deep infections should be actively searched for also among IDUs.
This trial was not designed to reveal possible differences between antibiotic treatments and the statistical power would neither enable such analysis. However, in accordance with positive results in experimental and animal studies we found lower mortality in SAB with a deep infection when the patients were treated with rifampicin in addition to standard treatment [20] [see Additional file 1]. In the present trial, most IDUs were also treated with rifampicin which might cause problems with drug interactions not least with methadone.
Overall mortality rate was significantly higher among nonaddicts (39%) than in addicts (10%) in accordance with 30% to 70% mortality previously reported in nonaddicts [1, 5, 14]. In earlier studies, poor prognosis has been associated with left-sided involvement, endocarditis of prosthetic valve, higher incidence of underlying diseases, central nervous system manifestations, and older age [1, 14, 19, 29]. Our trial showed that injection drug abuse in accordance with younger age and lack of severe underlying diseases were associated with better prognosis. There was a tendency for lower mortality in patients with right-sided IE but for higher mortality in patients with severe sepsis, left-sided involvement, and arterial embolic events. However, these factors did not achieve statistical significance probably due to insufficient sample size.
Conclusion
We concluded that endocarditis was more frequently connected to SAB among IDUs. In contrast to previous reports, addicts had equally often complications including extracardiac deep infections and arterial thromboembolic events as nonaddicts. In spite of this, mortality was significantly lower in IDUs in accordance with earlier data.
Acknowledgements
We thank the FINLEVO study group investigators for their invaluable participation in patient collection [see Additional file 1]. This study was supported by an unrestricted grant (ER, VV, and AJ) from Aventis Pharma and Pfizer Inc., and a grant from the special Finnish governmental subsidy for health sciences research (ER and AJ).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interests
Financial competing interests: ER has served as consultant to Aventis Pharma. AJ and VV have been consultants to several companies including Aventis Pharma, Bayer, Pfizer Inc., AstraZeneca, Roche, Pharmacia and Merck & Co, Inc. None of the authors had non-financial competing interests to disclose.
Authors' contributions
Authors ER, KS, JL, VV, and AJ participated in the design and coordination of the study. ER, KS, and JL made substantial contributions to acquisition of data. ER, KH, SS, VV, and AJ performed statistical analysis. All authors read and approved the final manuscript.